GSE211856
LNCAP xenograft prostate cancer progression model in NOD-SCID mice
Xenografts are useful in vivo tumour models for investigating cancer progression, therapeutic responses and predicting anti-cancer drug response in patients with cancer of a similar phenotype. We have generated bulk RNA-seq data from LNCaP xenografts of a large and well-annotated prostate cancer progression study, investigating responsiveness and subsequent resistance to therapies targeting the androgen receptor (AR). LNCaP xenograft tumour establishment and initial growth are dependent on androgens in male mice (PRE-CX / pre-castration group). Upon castration, AR activity and tumour growth are suppressed (POST-CX / post-castration group), however, this initial responsiveness to castration reproducibly gives way to castration-resistance (CRPC / castration-resistant prostate cancer).  Further treatment of CRPC with the AR targeting drug enzalutamide (ENZ) initially provides a therapeutic response (ENZ Sensitive; ENZS), however, resistance emerges in time (ENZ Resistant; ENZR). Overall design: 54 samples, multiple biological repeats of each condition/treatment group: PRE-CX (pre-castration / intact, 9), POST-CX (post-castration, 8), CRPC (castrate-resistant, 10), ENZ (enzalutamide treated, 27 = 12 ENZS and 15 ENZR).